Atopic Eczema clinical trials

Explore recruiting atopic eczema clinical trials.

Recruiting atopic eczema studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atopic Eczema trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry.

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IV, non-randomized, open-label multinational trial to assess the mechanism of action for Lebrikizumab in moderate-to-severe atopic dermatitis

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)

Sweden, France, Czechia, Germany, Portugal, Belgium +3 more

Phase III and phase IV (Integrated) EU CTIS Study details

A phase IV randomised, double-blind, parallel-design, controlled multi-center trial of a NOVel moisturiser for Atopic dermatitis: effect on relapse prevention in children, NOVA II

Germany, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A phase I/II randomized, assessor-blind, vehicle-controlled study to assess the safety, tolerability, and pharmacodynamics of DLQ03 in a wound healing model in patients with mild to moderate atopic dermatitis that are colonized with S. Aureus

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

B7451023 - A 16-Week, Multicenter, Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate Efficacy and Safety of Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Hungary, Poland, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Atopic Eczema trials by city

Atopic Eczema in Toronto Atopic Eczema in Vancouver Atopic Eczema in Montreal Atopic Eczema in Calgary Atopic Eczema in Edmonton Atopic Eczema in Ottawa Atopic Eczema in Winnipeg Atopic Eczema in Quebec City Atopic Eczema in Hamilton Atopic Eczema in Kitchener Atopic Eczema in London Atopic Eczema in Halifax Atopic Eczema in New York Atopic Eczema in Los Angeles Atopic Eczema in Chicago Atopic Eczema in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease